Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and Europe. The company is headquartered in Golden Valley, Minnesota.
| Revenue (TTM) | $898.74M |
| Gross Profit (TTM) | $774.11M |
| EBITDA | $71.33M |
| Operating Margin | -0.26% |
| Return on Equity | 18.00% |
| Return on Assets | 3.92% |
| Revenue/Share (TTM) | $31.04 |
| Book Value | $28.56 |
| Price-to-Book | 2.42 |
| Price-to-Sales (TTM) | 2.27 |
| EV/Revenue | 1.897 |
| EV/EBITDA | 19.78 |
| Quarterly Earnings Growth (YoY) | 308.40% |
| Quarterly Revenue Growth (YoY) | -7.60% |
| Shares Outstanding | $28.91M |
| Float | $23.28M |
| % Insiders | 1.18% |
| % Institutions | 130.30% |
Volatility is currently expanding
Inspire Medical is navigating a major product transition as clinical evidence, patient access efforts and reimbursement progress support growth prospects.
Medical Systems, American Well and Butterfly Network have been highlighted in this Industry Outlook article.
INSP, AMWL and BFLY are positioned to gain from digital health and AI demand despite cybersecurity risks.
MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026.
Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.
Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.
ALGT, HMC, INSP, AII and ALL have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2026.
Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.
Inspire Medical raised its 2026 outlook after a Q2 beat, as Inspire V mix and cost control offset weak U.S. procedure activity.
Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on INSP and any ticker you trade — then tracks every position and per-strategy win rate.
